Breaking Finance News

Oppenheimer announced Seres Therapeutics Inc (NDAQ:MCRB), boosting its stock price target to $19.00 today

In a report released on 10/13/2017 Oppenheimer increased the stock price target of Seres Therapeutics Inc (NDAQ:MCRB) to $19.00 reporting a possible upside of 0.73%.

Previously on 08/04/2017, H.C. Wainwright released a statement about Seres Therapeutics Inc (NDAQ:MCRB) increased the target price from $15.00 to $19.00. At the time, this indicated a possible upside of 0.38%.

Just yesterday Seres Therapeutics Inc (NDAQ:MCRB) traded 1.10% higher at $10.98. Seres Therapeutics Inc’s 50-day moving average is $14.20 and its 200-day moving average is $14.20. The last stock price is down -22.61% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.03% over the same time period. 361,110 shares of MCRB traded hands, up from an average trading volume of 288,375

Recent Performance Chart

Seres Therapeutics Inc (NDAQ:MCRB)

Seres Therapeutics Inc has 52 week low of $8.85 and a 52 week high of $17.42 and has a market capitalization of $0.

In addition to Oppenheimer reporting its stock price target, a total of 7 brokerages have issued a ratings update on the company. The average stock price target is $43.71 with 5 brokerages rating the stock a strong buy, 1 brokerage rating the stock a buy, 1 brokerage rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.

Brief Synopsis On Seres Therapeutics Inc (NDAQ:MCRB)

Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI; SER-287 and SER-301, to treat inflammatory bowel disease (IBD), including ulcerative colitis, and SER-155 to treat enteric bacterial pathogens.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.